You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
Kedrion Biosc - Front Image

news

  1. 16-10-2019

    FSI SGR enters Kedrion share capital

    The company continues with its growth and development strategy

    read more 
  2. 13-08-2019

    FIRST HALF RESULTS 2019

    Kedrion increased its turnover by 30.8% reaching Euro 364.0 million

    read more 
  3. 08-05-2019

    FY 2018 Results General Investor Call

    9 May at 10.00 GMT / 11.00 CET

    read more 
  4. 29-04-2019

    Annual General Meeting of Shareholders 2019

    Kedrion’s shareholders approve financial statements for fiscal year 2018

    read more 
  5. 29-03-2019

    ANNUAL RESULTS 2018

    Consolidated turnover of Euro 687.9 million, up 14,2%, and adjusted EBITDA of Euro 148.7 million

    read more 
  6. 27-03-2019

    Kedrion announces FDA Approval for Rhogam® Fill and Finish in Melville

    Approval received for aseptic filling, visual inspection, labelling/packaging and associated analytical testing operations

    read more 

Pages

For more information please contact: investor@kedrion.com